· SME · BSE
Price Band
₹41–43
Lot Size
3000 shares
Issue Size
₹12 Cr
Min. Investment
₹1,29,000
Indicative, updates through the day
Cap price plus current GMP: ₹43 — arithmetic, not a forecast
Subscription data will appear once bidding opens.
Goldline Pharmaceutical IPO is an SME issue that listed on BSE on 19 May 2026. The issue price band is fixed at ₹41–₹43 per equity share with a minimum market lot size of 3000 shares, bringing the total issue size to ₹12 Cr. At the upper price band, the minimum retail application requires one lot amounting to ₹1,29,000.
No meaningful grey market premium is actively quoted for Goldline Pharmaceutical IPO at this stage. For an SME issue at this point in the timeline, this is standard until anchor book allocations and institutional bids build volume. A missing premium is not negative sentiment; it reflects lower off-market liquidity. Read our complete guide to IPO GMP mechanics.
The minimum investment for retail investors is one lot of 3000 shares (approx. ₹1,29,000 at the cut-off price). Applications must be submitted using ASBA via Net Banking or the UPI Mandate route through registered stockbrokers (Zerodha, Groww, Angel One, Upstox).
The official registrar appointed for this issue is Bigshare Services Pvt. Ltd., with the basis of allotment finalised on 15 May 2026 and listing completed on 19 May 2026. Once declared, you can check your allotment status on our IPO Allotment Checker using your PAN or Application Number. If you are not allotted shares, the ASBA block on your bank funds is automatically released by T+2 day.
Issue Price
₹43
Listed At
₹59.75
Current Price
₹56.77
Goldline Pharmaceuticals is engaged in the business of marketing pharmaceutical products under the brand name “Goldline.” Its product range is divided into five segments: The company do not manufacture products, it partner with third-party manufacturers who produce the medicines based on its market research and product specifications, ensuring quality and compliance with regulations. All products are marketed and sold under the Goldline brand through our network of distributors, who supply to retailers and wholesalers. The company currently works with 15 manufacturers and 7 distributors, and it also support hospitals and healthcare providers with procurement and material supply. The company sells products across the states of Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.
Goldline Pharmaceutical IPO raises ₹3.15 crore from anchor investors. Goldline Pharmaceutical IPO Anchor bid date is May 11, 2026.
| Category | Shares Offered | % |
|---|---|---|
| QIB | 12,72,000 | 49.65% |
| − Anchor Investor | 7,32,000 | 0% |
| − QIB (Ex. Anchor) | 5,40,000 | 0% |
| NII (HNI) | 3,90,000 | 15.22% |
| − bNII > ₹10L | 2,58,000 | 0% |
| − sNII < ₹10L | 1,32,000 | 0% |
| Retail | 9,00,000 | 35.13% |
| Market Maker | 1,38,000 | 0% |
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (IND) (Min) | 2 | 6000 | ₹2,58,000 |
| Individual investors (IND) (Max) | 2 | 6000 | ₹2,58,000 |
| S-HNI (Min) | 3 | 9000 | ₹3,87,000 |
| S-HNI (Max) | 7 | 21000 | ₹9,03,000 |
| B-HNI (Min) | 8 | 24000 | ₹10,32,000 |
EPS (Pre IPO)
4.11
EPS (Post IPO)
3.09
ROE
17.99%
P/E (Pre IPO)
10.47
P/E (Post IPO)
13.93
Price / Book
Market Cap
₹30Cr.
| Company | P/E | ROE | Revenue |
|---|---|---|---|
| Speciality Medicines Ltd. | 9.27 | ₹29.14 Cr | |
| Accretion Nutraveda Ltd. | 26.27 | ₹24.77 Cr | |
| KRM Ayurveda Ltd. | 17.32 | ₹77.49 Cr | |
| Curis Lifesciences Ltd. | 12.44 | ₹27.52 Cr | |
| Aptus Pharma Ltd. | 11.29 | ₹13.02 Cr | |
| Asston Pharmaceuticals Ltd. | 17.83 | ₹27.56 Cr |
Goldline Pharmaceutical Ltd. Address
Bigshare Services Pvt. Ltd.